Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. The company aims to integrate traditional biology research with advanced engineering to develop medicines more efficiently. Its initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. The company's leadership includes Dr. Roger M. Perlmutter, M.D., Ph.D., Chair and Chief Executive Officer, and Dr. Roy Baynes, M.D., Ph.D., Chief Medical Officer. Their broader leadership team consists of former senior leaders from global pharmaceutical companies with experience in the discovery, development, and commercialization of over 100 new molecular entities. Eikon Therapeutics' strategy involves deploying its technology platform, including its proprietary single molecule tracking (SMT) system, to develop internally-derived novel therapies. The company also leverages its management team's expertise to opportunistically in-license promising assets. Its most advanced product candidate, EIK1001, a toll-like receptor (TLR) 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial. This trial is evaluating EIK1001 in combination with pembrolizumab for the treatment of patients with advanced melanoma.